“I anti-diabetes slimming drugsGLP-1 receptor agonists, have been in the news for the past couple of years and many of you will have heard of them. The ones most in short supply in the EU are Ozempic, Saxenda, Trulicity, Victoza, and these drugs are everywhere, from online discussions on social media to public statements by celebrities, and they are becoming part of popular culture, so we hear a lot of noise. But we cannot ignore that there is also an increase inuso off-label by people who do not suffer from diabetes or obesity and who see Glp-1 agonists as a possible miracle drug for weight loss. This off-label use must stop.” It’s the warning of Emer Cookeexecutive director of theEuropean Medicines Agency (EMA).
“As a medicines regulator,” the EMA representative explained during a press briefing, “we have a role to play in managing shortages, which is why we have provided recommendations at European level for all actors involved, to ensure that these medicines are preserved for those who need them most. The persistently high demand for GLP-1 receptor agonist weight-loss diabetes medicines has also attracted criminal activity, increasing the risk of falsified products entering the market with serious consequences for public health.”
Advertisements
For drugs from this family since 2022 there has been asurge in demand. This boom in demand, together with other issues such as production capacity limitations, have led to shortages across the EU (and beyond). “The EMA and the EU network of regulators – reads a note – are closely monitoring the situation and taking several actions from 2022”. The recommendations of the Mssg group mark “the next stage in the coordinated response to the current shortcomings”.
Nurse Times editorial team
Related Articles
Find out how to earn money by publishing your thesis on NurseTimes
The NEXT project is renewed and becomes NEXT 2.0: we publish the questionnaires and your theses
Upload your thesis:tesi.nursetimes.org
Upload your questionnaire: https://tesi.nursetimes.org/questionari
 of anti-diabetes drugs”){kind=link}